Navidea Biopharmaceuticals Schedules Conference Call to Discuss Future Outlook and Outcomes of Court Trial
04 April 2018 - 2:48AM
Business Wire
Conference call to take place Thursday April 5,
2018 at 8:30am E.T.
Navidea Biopharmaceuticals (NYSE MKT: NAVB) (“Navidea” or “the
Company”), a company focused on the development of precision
immunodiagnostic agents and immunotherapeutics, today
announced it will host a conference call on April 5, 2018 at 8:30am
E.T. to discuss its future outlook following the outcome of the
court case in Texas with Capital Royalty Group (CRG).
Michael Goldberg, President and Chief Executive Officer, and Jed
Latkin, Chief Financial and Operating Officer of Navidea, will host
the call and provide an update on recent developments and the
strategy going forward.
To participate in the call, please dial +1 929-477-0448
(toll-free) in the U.S. and Canada. The conference ID number is
6756561.
Event: Navidea Future Outlook and Trial Outcome Call
Date: Thursday, April 5, 2018
Time: 8:30am E.T.
U.S. & Canada Dial-in: +1 929-477-0448 (toll free)
Conference ID: 6756561
A live audio webcast of the conference call will also be
available on the investor relations page of Navidea’s corporate
website at www.navidea.com. In addition, the recorded conference
call can be replayed and will be available for 90 days following
the call on Navidea’s website.
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a
biopharmaceutical company focused on the development of precision
immunodiagnostic agents and immunotherapeutics. Navidea is
developing multiple precision-targeted products based on its
Manocept™ platform to enhance patient care by identifying the
sites and pathways of disease and enable better diagnostic
accuracy, clinical decision-making, and targeted treatment.
Navidea’s Manocept platform is predicated on the ability to
specifically target the CD206 mannose receptor expressed on
activated macrophages. The Manocept platform serves as the
molecular backbone of Tc 99m tilmanocept, the first product
developed and commercialized by Navidea based on the platform. The
development activities of the Manocept immunotherapeutic platform
are being conducted by Navidea in conjunction with its subsidiary,
Macrophage Therapeutics, Inc. Navidea’s strategy is to deliver
superior growth and shareholder return by bringing to market novel
products and advancing the Company’s pipeline through global
partnering and commercialization efforts. For more information,
please visit www.navidea.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180403006277/en/
Navidea Biopharmaceuticals, Inc.Jed Latkin, CFO/COO,
614-973-7490jlatkin@navidea.comorEdison AdvisorsTirth Patel,
646-653-7035tpatel@edisongroup.com
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Apr 2024 to May 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From May 2023 to May 2024